ERYTHROPOIETIN GENE DELIVERY FOR MYOCARDIAL INFARCTION TREATMENT

Myocardial infarction is the leading cause of morbidity and mortality worldwide. Although cardiac remodeling can maintain normal function initially, it gradually becomes maladaptive, leading to adverse outcomes, including heart failure. A novel approach for delivering plasmid human erythropoietin gene through an Arginine-grafted Bioreducible Polymer shows promise as a gene therapy tool for treating myocardial infarction. This treatment reverses post-infarct cardiac remodeling and restores heart function. Research suggests that this bioreducible delivery vector can revive the therapeutic potential of erythropoietin and other cardioprotective genes, allowing use as an effective treatment.